Eddingpharm In-licenses Second CV Drug from Cardiome

Eddingpharm in-licensed greater China rights to a second drug from Canada's Cardiome: Aggrastat ® (tirofiban hydrochloride), an anti-platelet therapy. In December 2014, Eddingpharm in-licensed China rights to Brinavess ® (vernaklant), a Cardiome treatment for atrial fibrillation. Eddingpharm, which must conduct clinical trials for both drugs, agreed to make milestone payments and also committed to minimum annual commercial sales. Both drugs will be marketed to cardiovascular specialists. More details.... Stock Symbols: (NSDQ: CRME; TSX: COM) Share this with colleagues: // //